|
|
|
|
| LEADER |
02482nmm a2200361 u 4500 |
| 001 |
EB000368910 |
| 003 |
EBX01000000000000000221962 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
130626 ||| eng |
| 020 |
|
|
|a 9783211782071
|
| 100 |
1 |
|
|a Mulzer, Johann H.
|e [editor]
|
| 245 |
0 |
0 |
|a The Epothilones: An Outstanding Family of Anti-Tumor Agents
|h Elektronische Ressource
|b From Soil to the Clinic
|c edited by Johann H. Mulzer
|
| 250 |
|
|
|a 1st ed. 2009
|
| 260 |
|
|
|a Vienna
|b Springer Vienna
|c 2009, 2009
|
| 300 |
|
|
|a IX, 260 p
|b online resource
|
| 505 |
0 |
|
|a General Aspects -- Biosynthesis and Heterologous Production of Epothilones -- Total Synthesis of Epothilones A-F -- Semisynthetic Derivatives of Epothilones -- Preclinical Pharmacology and Structure-Activity Studies of Epothilones -- Clinical Studies with Epothilones
|
| 653 |
|
|
|a Medicinal chemistry
|
| 653 |
|
|
|a Chemistry, Organic
|
| 653 |
|
|
|a Bioorganic Chemistry
|
| 653 |
|
|
|a Chemistry, Technical
|
| 653 |
|
|
|a Bioorganic chemistry
|
| 653 |
|
|
|a Biotechnology
|
| 653 |
|
|
|a Medicinal Chemistry
|
| 653 |
|
|
|a Industrial Chemistry
|
| 653 |
|
|
|a Organic Chemistry
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 490 |
0 |
|
|a Fortschritte der Chemie organischer Naturstoffe Progress in the Chemistry of Organic Natural Products
|
| 028 |
5 |
0 |
|a 10.1007/978-3-211-78207-1
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-211-78207-1?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 547
|
| 520 |
|
|
|a Epothilones have received unusual attention over the past ten years. They are novel antitumor drugs which very much like their predecessor paclitaxel (Taxol) act via microtubule stabilization. In comparison to paclitaxel and a number of alternative drugs with a similar mode of bioaction (e.g. laulimalide, eleutherobin, peluroside, discodermolide) the epothilones have significant advantages, above all very high activity in the nanomolar range and low susceptibility towards multidrug resistance. Epothilone B and several derivatives thereof are in phase I-III clinical trials; one of them (ixabepilone, BMS) is already on the market, others are supposed to appear on the market in the near future. All naturally occurring epothilones have been isolated from Sorangium cellulosum; their antitumor action is traced back to the stabilization of microtubules. In consequence, the formation of the mitototic spindle is prohibited and the cell undergoes apoptosis
|